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Introduction
The assessment of arterial wall healing following DES implan-
tation with the use of optical coherence tomography (OCT) has 
become a standard in the systematic evaluation of coronary stents. 
As a result, the number of scientific manuscripts on stents and 
OCT has proliferated, and stent characteristics including strut 
coverage and malapposition are reported based on their associa-
tion with stent thrombosis in observational studies1. In this issue of
Article, see page 1389
EuroIntervention, Kim and colleagues2 present the results of a ran-
domised comparison between new-generation biodegradable bioli-
mus-eluting stents (BES; Nobori®; Terumo Corp., Tokyo, Japan) and 
early-generation sirolimus-eluting stents (SES; Cypher®; Cordis, 
Johnson & Johnson, Warren, NJ, USA). In a cohort comprising 120 
patients with predominantly stable coronary artery disease, uncov-
ered struts were observed in 15.9% of BES and 25% of SES-treated 
patients (p=0.003). Consistent with improved strut coverage, a thicker 
neointimal layer in BES (52 µm [41.9-74.9]) compared with SES-
treated lesions (42 µm [30.6-56.0, p=0.005]) was observed. A con-
tour plot analysis displaying the spatial distribution of uncovered 
stent struts showed a more diffuse pattern of uncovered struts follow-
ing SES implantation. Malapposed stent struts were numerically 
lower in BES (0.5%) than in SES-treated patients (1.0%, p=0.21).
In synthesis, the study suggests a superior healing profile of the 
biodegradable polymer BES as compared to the durable polymer 
SES. These results are largely confirmatory of previous OCT 
studies assessing stent-vessel wall interactions at later time points3. 
Owing to the relatively large number of stents and the random allo-
cation of stent type, these data contribute importantly to the avail-
able literature on this topic. The assessment of strut coverage prior 
to full biodegradation of the polymer is somewhat debatable as any 
benefit associated with biodegradable polymers may occur weeks 
to months after completion of the biodegradation process.
Compared to previous OCT reports, the present study observed 
a higher frequency of uncovered stent struts in SES-treated lesions 
(approximately 40-50% higher)4-6, while reference studies for BES 
at six months are lacking. This discrepancy raises two important 
issues related to OCT studies: first, the assessment of strut coverage 
is delicate with considerable intra- and inter-observer variability7. 
Only trained image analysts with a proven reproducibility record 
should be involved in strut coverage analyses using appropriate 
definitions. Second, the characteristics of OCT datasets require 
careful consideration when analysing and interpreting OCT 
publications8.
Characteristics of OCT datasets
Data from intravascular OCT are inherently hierarchical. The low-
est sampling units are struts, nested within lesions, which are in turn 
nested within patients. Clinically, it is of interest to predict how 
lesions will respond to the implantation of a particular stent type, 
while the response of an individual strut is of subordinate impor-
tance. Intuitively one might assume that strut characteristics 
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correlate within lesion and patient. This correlation needs to be 
accounted for when performing statistical analyses. Depending on 
the model applied, results and conclusions may change substan-
tially and this also sheds light on the findings in the present study.
Differences in analytical approach
To illustrate differences among a variety of analytical approaches, 
we used an existing OCT dataset9 on malapposition, which is shown 
in Figure 1. Percentage estimators, confidence intervals (CIs), and 
p-values were obtained by the following five methods, which have 
all been used for OCT analyses in the literature. Analyses were per-
formed with the computing environment R and packages ime4 and 
geepack10-12.
CRUDE ANALYSIS
The percentage of all pooled struts is reported; CI and p-value 
ignore that struts are nested within lesions. This method falsely 
leads to small p-values and narrow CIs which ignores that struts 
from the same lesion are not independent.
GENERALISED ESTIMATING EQUATION MODEL (GEE)
Percentage estimators, CIs and p-values are obtained from a GEE 
model. The study of Kim et al used this approach to compute p-val-
ues. These percentage estimators are closely related to the percent-
ages from the crude analysis but the GEE model takes into account 
that struts from the same lesion are correlated and gives valid CIs 
and p-values.13-15
NON-PARAMETRIC ANALYSIS OF AGGREGATED DATA
The lesion-level percentage is first obtained separately for each 
lesion and then the median of these percentages is reported as the 
overall percentage estimator. No CIs are computed. P-values are 
obtained from the Wilcoxon rank-sum test because it is a rank-
based method which is valid for asymmetrical distributions as are 
present here (black dots in Figure 1)15-17.
MULTILEVEL MODEL
Percentage estimators, CIs and p-values are obtained from a multi-
level logistic regression model, which implicitly derives lesion-spe-
cific percentages and provides an overall percentage estimator that 
is centred on these lesion-specific percentages. Models are esti-
mated with the maximum likelihood approach18.
BAYESIAN MULTILEVEL MODEL
The multilevel logistic regression model as described above is esti-
mated with a Bayesian approach based on uninformative priors3,9.
The results obtained by the individual methods are presented in 
Table 1 and Figure 1.
Non-parametric analysis of aggregated data
The interpretation of the median is simple and lesion-oriented: half 
of the lesions have a percentage above and the other half below 
the reported median. However, when data contain a large propor-
tion of lesions with a value of 0%, confidence intervals cannot be 
computed.
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Figure 1. Representation of the dataset. Each black dot represents the lesion-level percentage of malapposed struts. Results of the crude 
analysis, GEE, and multilevel model are represented as confidence curves, which summarise CIs for several confidence levels; the peaks of the 
curves represent the percentage estimators given in Table 1. For the aggregated data analysis, only the median is indicated (pink diamond).
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Multilevel model
The multilevel model gives percentage estimators consistent with 
the median from the aggregated analysis method (Figure 1, Table 1), 
which is to be expected because it implicitly models the lesion-level 
percentages. It can be interpreted in a lesion-oriented manner. 
Estimation via frequentist or Bayesian methods leads to almost 
exactly the same results.
Crude analysis and GEE
The crude and the GEE-based methods estimate the strut-level 
response. It has been shown that their percentage estimator is 
always closer to 50% compared to a multilevel model19,20. In our 
example, the crude and the GEE-based percentages are consistent 
with each other but clearly higher than percentages from the aggre-
gated and multilevel analysis methods (Figure 1, Table 1). As 
expected, the crude analysis method leads to p-values that are too 
small and CIs that are too narrow.
P-values
Multilevel models and GEEs account for the non-independence of 
struts within lesions. However, their p-values lead to different 
conclusions: GEE-based results indicate that malapposition is sig-
nificantly higher in SES-implanted lesions; multilevel models 
indicate that there is no significant difference (Table 1). The con-
clusion of the multilevel models is correct but only as a statement 
regarding the majority of lesions; however, it does not capture the 
response of a few lesions with the highest level of malapposition. 
These lesions must be handled separately as done for example in 
Räber et al9. The GEE results are mainly driven by a few lesions. 
If the four lesions with highest malapposition are excluded, the 
GEE-based p-value rises from 0.01 to 0.63. Without a graphical 
representation of the data (Figure 1), the GEE results are mislead-
ing because the reader cannot understand that the significance is 
due to a few lesions only.
Table 1. Comparison of different analytical approaches. All available 
lesions are used to compare the percentage of malapposed struts.
Malapposed struts (%)
SES (95% CI)
N=41 lesions 
N=6,380 struts
PES (95% CI)
N=47 lesions 
N=6,782 struts
p-value
Crude analysis* 4.2 (3.7 to 4.7) 2.1 (1.8 to 2.4) <0.00001
Generalised estimating equation 
modela 4.6 (2.7 to 7.9) 1.9 (1.3 to 2.9) 0.01153
Non-parametric analysis of 
aggregated data 1.0 1.1 0.32104
Multilevel modelb 1 1.2 (0.6 to 2.2) 0.7 (0.4 to 1.3) 0.23946
Bayesian multilevel modelb 2 § 1.2 (0.6 to 2.2) 0.7 (0.3 to 1.3) 0.23
* Notice that p-values and CIs of the crude analysis are not valid. a GEE with binomial 
response and exchangeable within-lesion correlation. b Generalised linear mixed model with 
binomial response and random intercept for lesions. 1 Maximum likelihood estimation. 
2 Bayesian estimation based on uninformative priors. § From Räber et al9, Table 5.
None of the methods captures the full distribution pattern of 
malapposition. A graphical representation where the clinically rel-
evant units (here: lesions) are plotted 9,18 should ideally be reported 
to allow a fully informed comparison of the groups. The multilevel 
and aggregated analysis methods are both correct if the percentage 
estimators are to be interpreted at lesion level. The GEE is a correct 
approach if the percentage estimators are to be interpreted at strut 
level, a scenario of little clinical relevance. Of note, the GEE-based 
p-value is adversely affected by lesion-level outliers (Figure 1, SES 
group). Percentage estimators from crude and GEE methods cannot 
be compared with percentage estimators from aggregated and mul-
tilevel methods. P-values and CIs of the crude method should not 
be used because they are not valid.
Conclusions
As for the study by Kim and colleagues, the reported percentage 
considerably overestimates the lesion-level percentage of uncov-
ered struts. P-values were assessed by a GEE and also by multilevel 
logistic regression (Online Table 1) and resulted in p-values con-
sistently above or below the nominal significance level. Therefore, 
a scenario where p-values were adversely affected by a few lesions 
can be ruled out. However, a superior healing profile of BES as 
compared to SES based on a significant difference between treat-
ment groups remains, and the conclusion on a superior healing 
response with the biodegradable stent platform appears valid.
The comparison of OCT data among different studies is lim-
ited not only by differences in patient population, follow-up 
duration and OCT interpretation, but also importantly by the sta-
tistical analysis. The fact that all five aforementioned methods 
have been used in the past represents a serious limitation for 
comparison across articles or meta-analyses of OCT-related stud-
ies. Although we suggest that multilevel approaches appear ideal 
for clinical OCT studies, the use of alternative methods may be 
appropriate.
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